- Home
- PKG vs RPRX Comparison
PKG vs RPRX Comparison
Compare PKG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKG
- RPRX
- Stock Information
- Founded
- PKG 1867
- RPRX 1996
- Country
- PKG United States
- RPRX United States
- Employees
- PKG N/A
- RPRX N/A
- Industry
- PKG Containers/Packaging
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- PKG Consumer Discretionary
- RPRX Health Care
- Exchange
- PKG Nasdaq
- RPRX Nasdaq
- Market Cap
- PKG 16.6B
- RPRX 14.2B
- IPO Year
- PKG 2000
- RPRX 2020
- Fundamental
- Price
- PKG $181.42
- RPRX $33.15
- Analyst Decision
- PKG Strong Buy
- RPRX Strong Buy
- Analyst Count
- PKG 6
- RPRX 4
- Target Price
- PKG $230.33
- RPRX $42.50
- AVG Volume (30 Days)
- PKG 809.4K
- RPRX 3.7M
- Earning Date
- PKG 04-22-2025
- RPRX 05-08-2025
- Dividend Yield
- PKG 2.75%
- RPRX 2.65%
- EPS Growth
- PKG 19.48
- RPRX 37.42
- EPS
- PKG 9.56
- RPRX 2.45
- Revenue
- PKG $8,544,799,999.00
- RPRX $2,263,576,000.00
- Revenue This Year
- PKG $6.99
- RPRX $31.30
- Revenue Next Year
- PKG $3.46
- RPRX $5.82
- P/E Ratio
- PKG $19.05
- RPRX $13.54
- Revenue Growth
- PKG 9.47
- RPRX 1.12
- 52 Week Low
- PKG $172.72
- RPRX $24.05
- 52 Week High
- PKG $250.82
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- PKG 42.67
- RPRX 57.43
- Support Level
- PKG $178.30
- RPRX $31.97
- Resistance Level
- PKG $184.53
- RPRX $34.11
- Average True Range (ATR)
- PKG 5.15
- RPRX 0.71
- MACD
- PKG 0.15
- RPRX 0.09
- Stochastic Oscillator
- PKG 31.58
- RPRX 62.06
About PKG Packaging Corporation of America
Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 4.5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.